Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318676 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT06318676 is a Phase 1 study of Renal Impairment that has completed, run by Celgene. The registered enrollment target is 26 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (24% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06318676, a Phase 1 study of Renal Impairment, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
Conditions Studied
Interventions
- DRUG Mezigdomide
Study Locations (3)
Florida
- PANAX - Miami Lakes
- Omega Research Group - Orlando - Orlando
- Orlando Clinical Research Center OCRC - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-03-21 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06318676
The ClinicalTrials.gov registry entry for NCT06318676 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (24% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Mezigdomide is the first listed.
NCT06318676 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06318676 about?
NCT06318676 is a clinical study titled "A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment". The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
What is the current status of trial NCT06318676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-03-21. Estimated completion is 2024-11-15.
What conditions does trial NCT06318676 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT06318676?
The interventions under investigation include: Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT06318676?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318676 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.